Lipodystrophy Clinical Trial
Official title:
A Phase IV, Prospective, Non-Blinded, Non-Randomized, Single-Center Clinical Trial to Determine the Longevity, Duration, and Volume-Correcting Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy
Lipoatrophy is a condition that affects certain individuals, most commonly those who are
infected with the HIV virus. Lipoatrophy however can also affect individuals who suffer from
recurrent systemic infections, those who have a weakened immune system, or certain patients
who suffer from cancer or receive chemotherapeutics. In contrast, lipoatrophy can sometimes
be present in individuals who are perfectly healthy but have genetically predisposing
factors that can contribute to facial emaciation or lipoatrophy.
The function of injectable fillers for the treatment of dermal contour deformities is to
smooth dermal depressions formed by the loss of volume. These often elastic contour fillers
(also known as soft tissue augmentation devices) can correct hollowness around the eyes, add
fullness to thin lips, balance a disproportionate face or correct topographical anomalies.
This study aims to:
- Objectively measure the improvement of contour-deformities after Sculptra™ injection
from baseline to study closure by utilizing the Primos™ photographic/topographical
measuring system.
- Evaluate the efficacy, longevity and duration of volume-correction in subjects which
are both HIV positive and HIV negative.
- Assess the safety of Scupltra™ dermal filler when used to correct volume deformities
caused by lipoatrophy in subjects that are HIV negative.
Status | Withdrawn |
Enrollment | 15 |
Est. completion date | December 2008 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Bilateral lipoatrophy corresponding to a visual grade 2 or above in the attached lipoatrophy scale. 2. Available and willing to attend all follow-up visits. 3. Age > 18 years. 4. Able and willing to give informed consent. Exclusion Criteria: 1. Known allergy or sensitivity to Sculptra™, suture material or any material that in the investigator's opinion may cause an allergic reaction. 2. The subject has received a soft tissue augmentation to the area to be treated within the last 6 months. 3. Subject is unwilling to forgo any cosmetic augmentation procedures for the duration of the study. 4. The subject has received autologous fat transfer in the last 6 months. 5. Subject is suffering from facial Kaposi's sarcoma. 6. The subject has active skin diseases or inflammation on or near the area of injection, such as psoriasis, herpes zoster, infection, or discoid lupus. 7. History of sensitivity to lidocaine. 8. Pregnant or nursing. (Premenopausal or nonsurgically sterile women must have a negative urine pregnancy test and must be using an adequate method of birth control.) 9. Subject has ever received an injection or implant of silicone in the area to be treated. 10. Subject is currently on any metabolic augmentation medications such as anabolic steroids. 11. Current use of anticoagulant therapy or has a history of hemorrhagic disorders. 12. History of connective tissue disease or other related disorder that in the investigator's opinion excludes the subject from the study. 13. Subject is involved in any other research study involving an investigational product, or has concluded a study less than 30 days ago. 14. The subject is suffering from any medical condition or complication that in the investigator's opinion places the subject at risk by participating in the study. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Dermatology Cosmetic Laser Associates of La Jolla | La Jolla | California |
Lead Sponsor | Collaborator |
---|---|
Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc. | Sanofi |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Volume correction and longevity of correction | at 12 and 24 months | ||
Secondary | Safety in non-HIV positive subjects |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05419037 -
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
|
||
Recruiting |
NCT03059121 -
The Cleveland Cardiometabolic Cohort
|
||
Completed |
NCT00656175 -
Raltegravir Therapy for Women With HIV and Fat Accumulation
|
Phase 2 | |
Completed |
NCT00006185 -
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
|
Phase 1 | |
Completed |
NCT00202241 -
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
|
N/A | |
Recruiting |
NCT02262832 -
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
|
Phase 3 | |
Completed |
NCT01679197 -
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
|
Phase 2 | |
Completed |
NCT02647853 -
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT00715546 -
Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy
|
Phase 1 | |
Completed |
NCT00069004 -
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
|
N/A | |
Completed |
NCT00025883 -
Leptin to Treat Lipodystrophy
|
Phase 2 | |
Completed |
NCT00001142 -
Metabolism and Body Shape of Healthy Children and Children With Chronic Infections
|
N/A | |
Active, not recruiting |
NCT02262806 -
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
|
Phase 2 | |
Completed |
NCT02258685 -
Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
|
||
Completed |
NCT00192621 -
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
|
Phase 4 | |
Completed |
NCT00006190 -
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
|
Phase 4 | |
Recruiting |
NCT05930106 -
Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management
|
N/A | |
Completed |
NCT00004329 -
Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
|
N/A | |
Recruiting |
NCT04656054 -
Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
|
||
Completed |
NCT00082628 -
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
|
Phase 3 |